Episode 2 of "Not So Different: a Podcast From the Center for Biosimilars"

February 18, 2018

In this episode of Not So Different, you’ll hear providers and patient advocates on the issue of nonmedical switching among brand-name biologics and biosimilars in rheumatology and oncology indications.

In our first episode, we brought you a discussion of biosimilar interchangeability from experts across the biosimilars landscape. Interchangeable biosimilars haven’t yet become a reality in the US marketplace, and, as of yet, there is no pharmacy-level substitution of interchangeable biosimilars for brand-name products.

However, patients and their providers may still face a change of biologic therapies when payers institute a nonmedical switch.

In today’s episode of Not So Different, you’ll hear providers and patient advocates on the issue of nonmedical switching among brand-name biologics and biosimilars in rheumatology and oncology indications.